Bob Leibenluft is a Partner in the Washington, D.C. office of Hogan Lovells. Mr. Leibenluft's practice is devoted entirely to health and antitrust matters, including counseling and litigation regarding antitrust issues in the health, medical device, and pharmaceutical industries.
Upon completing law school, Mr. Leibenluft worked as an attorney advisor in the Federal Trade Commission (FTC)'s Office of Policy Planning, concentrating on health and antitrust matters. In 1981, he joined Hogan & Hartson (now Hogan Lovells) and became a partner in the firm in 1989. He practiced health law at Hogan & Hartson until January 1996 when he rejoined the FTC as Assistant Director for Health Care in the FTC’s Bureau of Competition.
As head of the Health Care Division, he supervised a 25-30 person staff engaged in the review of mergers, acquisitions, and joint ventures involving hospitals, physicians, and other healthcare providers, as well as conduct in the healthcare and pharmaceutical industries. While at the FTC, he supervised the 1996 revisions of the FTC and DOJ Statements of Antitrust Enforcement Policy in Health Care in which the Agencies first addressed clinical integration. He rejoined Hogan & Hartson in September 1998.
Mr. Leibenluft is an inaugural fellow of the American Health Lawyers Association, where he previously served as a Vice President and member of the Board of Directors. He is a former Chair of the ABA Antitrust Section Joint Conduct Committee, Health and Pharmaceuticals Committee and State Enforcement Committee. He is Chair of the Board of Directors of HCI3, the parent company of Prometheus Payment Inc. and Bridges to Excellence. He is also an adjunct law professor at the George Washington Law School where he teaches a course on Antitrust in the Health Care Sector.
Mr. Leibenluft received his B.A. from Yale University and later received his J.D. from the University of California, Berkeley.
He is a co-author of Bloomberg BNA Corporate Practice Portfolio Series No. 90, Antitrust Compliance.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)